STOCKS TELEGRAPH

Tag: BioXcel

  • BioXcel (BTAI) Stock Climbs As FDA Clears Clinical Trial Site Inspection

    BioXcel (BTAI) Stock Climbs As FDA Clears Clinical Trial Site Inspection

    Following a significant regulatory update, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) stock saw a sharp increase in value. As of the recent market check, BTAI stock price rose by 96.14%, reaching $4.20. This significant rise is a reaction to recent events involving the FDA’s (U.S. Food and Drug Administration) assessment of its clinical trial location.

    Reaching a Regulatory Milestone

    The FDA has finished inspecting one site in the TRANQUILITY II Phase 3 study, according to BioXcel. The inspection status was closed and an Establishment Inspection Report was issued by the agency in accordance with 21 C.F.R. 20.64(d)(3). Although minor concerns may have been found, the site was classified as “Voluntary Action Indicated,” which means that regulatory action is not necessary.

    The completion of this inspection, together with the positive results of an independent audit carried out in October 2023, further confirms the accuracy of the trial data, BTAI stressed.

    These results will be included in a prospective supplementary new drug application (sNDA) filing for regulatory evaluation, according to BioXcel. Furthermore, BTAI is proceeding with its primary neuroscience candidate, BXCL501, after receiving FDA comments on the plan for its TRANQUILITY In-Care Phase 3 study.

    Promoting Clinical Development

    BXCL501 is a patented sublingual film formulation of the selective alpha-2 adrenergic receptor agonist dexmedetomidine that has received FDA approval. It is sold under the brand name IGALMI. The experimental formulation is now being studied for the treatment of acute agitation associated with schizophrenia, bipolar disorder, and Alzheimer’s dementia in home-based settings, despite having previously been licensed for certain uses.

    The TRANQUILITY In-Care Trial

    The 12-week, double-blind, placebo-controlled TRANQUILITY In-Care study aims to assess the safety and efficacy of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer’s disease in a care facility setting. BioXcel Therapeutics expects more regulatory contacts as its clinical projects advance, which might affect how its drug development activities develop in the future.

  • Following The Validation Of Trial Results, BioXcel (BTAI) Stock Is Rising

    Following The Validation Of Trial Results, BioXcel (BTAI) Stock Is Rising

    BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares have exhibited a notable surge of 23.08%, reaching $2.88 in the present trading session, as per the most recent data.

    The BioXcel stock was trading in a range spanned from $2.83 to $3.35 during today’s market activity, with a substantial trading volume of over 50 million shares.

    The catalyst for this morning’s ascent in BTAI stock can be attributed to a positive evaluation by an external party concerning the results of its clinical trial.

    Today, BioXcel (BTAI) unveiled encouraging outcomes stemming from an impartial third-party assessment of data from a specific site within its TRANQUILITY II Phase 3 trial.

    This audit, conducted by a well-respected regulatory and quality consulting firm, involved a thorough scrutiny of records pertaining to more than 50% of the trial’s participants at that specific site.

    The primary objectives of the audit encompassed the detection of any potential irregularities, misconduct, or fraudulent activities and an assessment of the integrity and reliability of the data pertaining to eligibility, safety, and efficacy.

    The sample size employed in this assessment ensures a 95% confidence level in the representativeness of the data reviewed.

    Following a comprehensive examination, the team of auditors did not uncover any elements that could compromise the reliability or integrity of the data, nor did they unearth any indications of further misconduct or fraud.

    Based on these findings, BioXcel has the belief that the positive and statistically significant data from the TRANQUILITY II trial, as announced in June 2023, could potentially serve as a basis for a supplemental new drug application (sNDA) for BXCL501, aimed at the acute treatment of agitation associated with dementia in probable Alzheimer’s disease.

    BioXcel is of the opinion that the results of this audit, conducted by a respected and independent entity, affirm the trustworthiness of the data originating from the specific site under scrutiny.

    Furthermore, these results enrich the body of clinical evidence that the company intends to incorporate into its sNDA submission.

    Notably, BTAI has recently conducted a Type B/Breakthrough meeting with the FDA to discuss the development plans for BXCL501 concerning the acute treatment of agitation in the context of dementia related to probable Alzheimer’s disease.

    BioXcel anticipates the receipt of the FDA meeting minutes in the first half of November and intends to provide an update on the subsequent phases of the TRANQUILITY program and the potential sNDA in its forthcoming third-quarter financial report.